Liselotte Hyveled: Exploring Opportunities to Improve Hemophilia and Sickle Cell Care in Ghana
Liselotte Hyveled, Vice President, Scientific Partnerships and Integration, Board Member at Novo Nordisk, shared a post on LinkedIn:
“Reflecting on an impactful week in Ghana
I am incredibly grateful to be on the ground with the Novo Nordisk Haemophilia and heamoglobinophahies Foundation (NNHF) and our partners, visiting local hospitals and patient organizations to deeply understand the care landscape for haemophilia and sickle cell disease in Ghana.
Our mission? To listen, learn, and identify the critical gaps and life-changing opportunities in treating these complex blood disorders.
Key Insights and Observations
- Resilient Patient Communities: Meeting with local patient organizations highlighted the immense strength of advocates who work tirelessly to raise awareness and support families despite limited resources.
- The Treatment Gap: While healthcare professionals in Ghana are deeply dedicated, systemic challenges—such as inconsistent access to life changing medications, affordable and consitent diagnostics, I can see are significant hurdles.
I hope we woth this trip identify the right places were we as a foundation can plug in and find the right opportunities for impact via meeting stakeholders here who can show us the best way for long term partnership and sustainable solutions.
No single organization can bridge these gaps alone.
It requires sustained, cross-sector collaboration between global foundations, local healthcare providers, ministries, and patient advocates to build a resilient healthcare ecosystem.
Thank you to all the medical professionals and patient leaders who opened their doors and shared their journeys with us.
Together, we can turn these identified opportunities into sustainable, life-saving realities.
This is just the beginning of a journey – Later this week we have a workshop with everyone and I so much look forward to more insight and discussions.
Thank you Mette Finderup Grove for your support.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series